Alexander Philipovskiy, MD, PhD, is Professor of Medical Oncology at Texas Tech University Health Sciences Center, where he serves as Director of Precision Oncology and Co-Director of the Breast Cancer Program. He is a medical oncologist and clinical investigator with expertise in breast cancer, precision oncology, molecularly guided treatment strategies, and early-phase drug development. Prior to joining TTUHSC, Dr. Philipovskiy served as Associate Director of the Drug Development Program at Florida Cancer Specialists & Research Institute, in partnership with Sarah Cannon Research Institute, where he was involved in the development and conduct of numerous Phase I and first-in-human oncology clinical trials, including studies of antibody-drug conjugates, immunotherapies, bispecific antibodies, and targeted agents. His academic interests include biomarker-driven oncology, translational drug development, clinical trial design, treatment sequencing, and expanding access to innovative cancer therapies for patients in underserved and rural communities.